Key result
Administration of rAAV expressing an anti-PrPC nanobody in mice exhibited a small but statistically significant therapeutic effect, extending survival time from 176 days to 184 days.
Why the study?
Nanobodies inhibit the conversion of PrPC to PrPSc in vitro, but the potential for in vivo expression and their impact on prion disease required evaluation.
Does ICV injection of anti-PrPC nanobody-expressing rAAV extend survival time in prion-inoculated mice?
Population
Newborn mice subsequently inoculated with prions intracerebrally at 5-6 weeks of age
Comparison
Three rAAV-packaged anti-PrPC nanobodies administered via intracerebroventricular injection
Design
Animal experimental study
Follow-up
Over 180 days
Authors
Loading...
Modest survival extension in prion mice warrants caution; leaves open whether AAV-nanobody delivery can be optimized for meaningful benefit.
Does ICV injection of anti-PrPC nanobody-expressing rAAV extend survival time in prion-inoculated mice?
Absolute Event Rate: 184% vs 176%
p-value: p=statistically significant
AAV-mediated delivery of anti-PrPC nanobodies in mice showed a small but statistically significant extension in survival time following prion inoculation, highlighting the need for further optimization.
Zhang et al. (2025) studied Prion disease. Anti-PrPC nanobodies packaged into recombinant adeno-associated virus (rAAV) vs. Control (implied) was evaluated on Survival time (p=statistically significant). Administration of rAAV expressing an anti-PrPC nanobody in mice exhibited a small but statistically significant therapeutic effect, extending survival time from 176 days to 184 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: